Chirality is a key factor in the safety and efficacy of many drug products and thus the production of single enantiomers of drug intermediates and drugs has become increasingly important in the pharmaceutical industry. There has been an increasing awareness of the enormous potential of microorganisms and enzymes derived there from for the transformation of synthetic chemicals with high chemo-, regio- and enatioselectivities. In this article, biocatalytic processes are described for the synthesis of chiral alcohols and unntural aminoacids for pharmaceuticals.
References
[1]
Food and Drug Administration. FDA’s statement for the development of new stereoisomeric drugs. Chirality？1992, 4, 338–340, doi:10.1002/chir.530040513.
[2]
Oliver, M.; Voigt, C.A.; Arnold, F.H. Enzyme engineering by directed evolution. In Enzyme Catalysis in Organic Synthesis, 2nd ed. ed.; VCH: New York, USA, 2002; Volume 1, pp. 95–138.
Schmidt, M.; Bauman, M.; Henke, E.; Konarzycka-Bessler, M.; Bornscheuer, U.T. Directed evolution of lipases and esterases. Meth. Enzymol.？2004, 388, 199–207, doi:10.1016/S0076-6879(04)88018-2.
[5]
Reetz, M.T.; Torre, C.; Eipper, A.; Lohmer, R.; Hermes, M.; Brunner, B.; Maichele, A.; Brunner, B.; Arand, M.; Cronin, A.; et al. Enhancing the enantioselectivity of an epoxide hydrolase by directed evolution. Org. Lett.？2004, 6, 177–180, doi:10.1021/ol035898m.
[6]
Rubin-Pitel, S.B.; Zhao, H. Recent advances in biocatalysis by directed enzyme evolution. Comb. Chem. High T. Scr.？2006, 9, 247–257.
[7]
Pollard, D.J.; Woodley, J.M. Biocatalysis for pharmaceutical intermediates: The future is now. Trends Biotechnol.？2007, 25, 66–73, doi:10.1016/j.tibtech.2006.12.005.
[8]
Otey, C.R.; Bandara, G.; Lalonde, J.; Takahashi, K.; Arnold, F.H. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotechnol. Bioeng.？2006, 93, 494–499, doi:10.1002/bit.20744.
[9]
Huisman, G.W.; Lalonde, J.J. Enzyme evolution for chemical process applications. In Biocatalysis in the Pharmaceutical and Biotechnology Industries; Patel, R.N., Ed.; CRC Press: Boca Raton, FL, USA, 2007; pp. 717–742.
[10]
Arnold, F.; Volkov, A. Directed evolution of biocatalysts. Curr. Opin. Chem. Biol.？1999, 3, 54–59, doi:10.1016/S1367-5931(99)80010-6.
[11]
Patten, P.A.; Howard, R.J.; Stemmer, W.P. Applications of DNA shuffling to pharmaceuticals and vaccines. Curr. Opin. Biotechnol.？1997, 8, 724–733, doi:10.1016/S0958-1669(97)80127-9.
Sylvestre, J.; Chautard, H.; Cedrone, F.M. Directed evolution of biocatalysts. Org. Process Res. Dev.？2006, 10, 562–571, doi:10.1021/op050243h.
[14]
Turner, N.J. Directed evolution drives the next generation of biocatalysts. Nat. Chem. Biol.？2009, 5, 567–573, doi:10.1038/nchembio.203.
[15]
Bornscheuer, U.T.; Huisman, G.W.; Kazlauskas, R.J.; Lutz, S.; Moore, J.C.; Robins, K. Engineering the third wave of biocatalysis. Nature？2012, 485, 185–194, doi:10.1038/nature11117.
[16]
Wells, A.S.; Finch, G.L.; Michels, P.C.; Wong, J.W. Use of enzymes in the manufacture of active pharmaceutical ingredients—A science and safety-based approach to ensure patient safety and drug quality. Org. Process Res. Dev.？2012, 16, 1986–1993, doi:10.1021/op300153b.
[17]
Reetz, M.T. Biocatalysis in organic chemistry and biotechnology: Past, present, and future. J. Am. Chem. Soc.？2013, 135, 12480–12496, doi:10.1021/ja405051f.
[18]
Huisman, G.W.; Collier, S.J. On the development of new biocatalytic processes for practical pharmaceutical synthesis. Curr. Opin. Chem. Biol.？2013, 17, 284–292, doi:10.1016/j.cbpa.2013.01.017.
[19]
Bryan, M.C.; Dillon, B.; Hamann, L.G.; Hughes, G.J.; Kopach, M.E.; Peterson, E.A.; Pourashraf, M.; Raheem, I.; Richardson, P.; Richter, D.; et al. Sustainable practices in medicinal chemistry: Current state and future directions. J. Med. Chem.？2013, 56, 6007–6021, doi:10.1021/jm400250p.
[20]
DiCosimo, R. Nitrilases and nitrile hydratases. In Biocatalysis in the Pharmaceutical and Biotechnology Industries; Patel, R.N., Ed.; CRC Press: Boca Raton, FL, USA, 2007; pp. 1–26.
[21]
Patel, R.N. Biocatalysis: Synthesis of chiral intermediates for pharmaceuticals. Curr. Org. Chem.？2006, 10, 1289–1321, doi:10.2174/138527206777698011.
[22]
Simeo, Y.; Kroutil, W.; Faber, K. Biocatalytic deracemization: Dynamic resolution, stereoinversion, enantioconvergent processes, and cyclic deracemization. In Biocatalysis in the Pharmaceutical and Biotechnology Industries; Patel, R.N., Ed.; CRC Press: Boca Raton, FL, USA, 2007; pp. 27–51.
[23]
Patel, R.N. Biocatalysis: Synthesis of key intermediates for development of pharmaceuticals. ACS Catal.？2011, 1, 1056–1074, doi:10.1021/cs200219b.
Zhao, H.; Chockalingom, K.; Chen, Z. Directed evolution of enzymes and pathways for industrial biocatalysis. Curr. Opin. Biotechnol.？2002, 13, 104–110, doi:10.1016/S0958-1669(02)00291-4.
[27]
Schulze, B.; Wubbolts, M. Biocatalysis for industrial production of fine chemicals. Curr. Opin. Biotechnol.？1999, 10, 609–611, doi:10.1016/S0958-1669(99)00042-7.
[28]
Steinreiber, A.; Faber, K. Microbial epoxide hydrolases for preparative biotransformations. Curr. Opin. Biotechnol.？2001, 12, 552–558, doi:10.1016/S0958-1669(01)00262-2.
[29]
Tao, J.; Xu, J.-H. Biocatalysis in development of green pharmaceutical processes. Curr. Opin. Chem. Biol.？2009, 13, 43–50, doi:10.1016/j.cbpa.2009.01.018.
[30]
Patel, R.N. Biocatalytic hydrolysis (esters, amides, epoxides, nitriles) and biocatalytic dynamic kinetic resolution. In Comprehensive Chirality; 2012; Volume 10, pp. 288–317.
[31]
Patel, R.N. Biocatalytic routes to chiral intermediates for development of drugs. In Biocatalysis for Green Chemistry and Chemical Process Development; Tao, J., Kazlauskas, R., Eds.; John Wiley & Sons, Inc.: Hoboken, USA city, 2010.
[32]
Jajoo, H.; Mayol, R.; LaBudde, J.; Blair, I. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab. Dispos.？1989, 17, 634–640.
[33]
Mayol, R. Buspirone Metabolite for the Alleviation of Anxiety. US6150365A, 6 June 2000.
[34]
Yevich, J.; New, J.; Lobeck, W.; Dextraze, P.; Bernstein, E.; Taylor, D.; Yocca, F.; Eison, M.; Temple, D., Jr. Synthesis and biological characterization of α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogs as potential atypical antipsychotic agents. J. Med. Chem.？1992, 35, 4516–4525, doi:10.1021/jm00102a002.
[35]
Yevich, J.; Mayol, R.; Li, J.; Yocca, F. (S)-6-Hydroxy-Buspirone for Treatment of Anxiety, Depression and Related Disorders. US2003022899, 30 January 2003.
[36]
Patel, R.; Chu, L.; Nanduri, V.; Jianqing, L.; Kotnis, A.; Parker, W.; Liu, M.; Mueller, R. Enantioselective microbial reduction of 6-oxo-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione. Tetrahedron Asymmetry？2005, 16, 2778–2783, doi:10.1016/j.tetasy.2005.07.015.
[37]
Goldberg, S.; Nanduri, V.; Chu, L.; Johnston, R.; Patel, R. Enantioselective microbial reduction of 6-oxo-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione: Cloning and expression of reductases. Enzyme Microb. Technol.？2006, 39, 1441–1450, doi:10.1016/j.enzmictec.2006.03.033.
Sit, S.; Parker, R.; Motoe, I.; Balsubramanian, H.; Cott, C.; Brown, P.; Harte, W.; Thompson, M.; Wright, J. Synthesis, biological profile, and quantitative structure activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. J. Med. Chem.？1990, 33, 2982–2999, doi:10.1021/jm00173a013.
[40]
Roth, B.D. The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog. Med. Chem.？2002, 40, 1–22, doi:10.1016/S0079-6468(08)70080-8.
[41]
Law, M.; Rudinka, A.R. Statin safety: A systematic review. Am. J. Cardiol.？2006, 97(8A), 52C–60C.
[42]
McTaggart, F.; Buckett, L.; Davidson, R.; Holdgate, G.; McCormick, A.; Schneck, D.; Smith, G.; Warwick, M. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol.？2001, 87, 28B–32B.
[43]
Guo, Z.; Chen, Y.; Goswami, A.; Hanson, R.L.; Patel, R.N. Synthesis of ethyl and t-butyl (3R,5S)-dihydroxy-6-benzyloxyhexanoates via diastereo- and enantioselective microbial reduction. Tetrahedron Asymmetry？2006, 17, 1589–1602, doi:10.1016/j.tetasy.2006.05.027.
[44]
Goldberg, S.; Guo, Z.; Chen, S.; Goswami, A.; Patel, R.N. Synthesis of ethyl-(3R,5S)-dihydroxy-6-benzyloxyhexanoates via diastereo- and enantioselective microbial reduction: Cloning and expression of ketoreductase III from Acinetobacter sp. SC 13874. Enzyme Microb. Technol.？2008, 43, 544–549, doi:10.1016/j.enzmictec.2008.07.005.
[45]
Davis, S.; Christopher, G.; John, H.; Gray, D.; Gruber, J.; Huisman, G.; Ma, S.; Newman, L.; Sheldon, R. Enzymatic Processes for the Production of 4-Substituted 3-Hydroxybutyric Acid Derivatives. US 7807423B2, 5 October 2010.
[46]
Jagoda, E.; Stouffer, B.; Ogan, M.; Tsay, H.M.; Turabi, N.; Mantha, S.; Yost, F.; Tu, J.I. Radioimmunoassay for hydroxyphosphinyl-3-hydroxybutanoic acid (SQ 33,600), a hypocholesterolemia agent. Ther. Drug Monit.？1993, 15, 213–219, doi:10.1097/00007691-199306000-00007.
[47]
Wang, D.I.; Arnold, M.E.; Jemal, M.; Cohen, A.I. Determination of SQ 33,600, a phosphinic acid containing HMG CoA reductase inhibitor, in human serum by high-performance liquid chromatography combined with ionspray mass spectrometry. Biol. Mass Spectrom.？1992, 21, 189–194, doi:10.1002/bms.1200210403.
[48]
Patel, R.; McNamee, C.; Banerjee, A.; Howell, J.; Robison, R.; Szarka, L. Stereoselective reduction of β-keto ester by Geotrich candidum. Enzyme Microb. Technol.？1992, 14, 731–738, doi:10.1016/0141-0229(92)90113-3.
[49]
Matsuyama, A.; Yamamoto, H.; Kobayashi, Y. Practical application of recombinant whole-cell biocatalysts for the manufacturing of pharmaceutical intermediates such as chiral alcohols. Org. Process Res. Dev.？2002, 6, 558–561, doi:10.1021/op025514s.
[50]
Zalman, L.S.; Brothers, M.A.; Dragovich, P.S.; Zhou, R.; Prins, T.J.; Worland, S.T.; Patick, A.K. Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother.？2000, 44, 1236–1241, doi:10.1128/AAC.44.5.1236-1241.2000.
[51]
Dragovich, P.S.; Prins, T.J.; Zhou, R.; Webber, S.E.; Marakovits, J.T.; Fuhrman, S.A.; Patick, A.K.; Matthews, D.A.; Lee, C.A.; Ford, C.E.; et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. incorporation of P1 lactam moieties as l-glutamine replacements. J. Med. Chem.？1999, 42, 1213–1224, doi:10.1021/jm9805384.
[52]
Tao, J.; McGee, K. Development of a continuous enzymatic process for the preparation of (R)-3-(4-fluorophenyl)-2-hydroxy propionic acid. Org. Process Res. Dev.？2002, 6, 520–524, doi:10.1021/op010232y.
[53]
Bold, G.; Faessler, A.; Capraro, H.-G.; Cozens, R.; Klimkait, T.; Lazdins, J.; JMestan, J.; Poncioni, B.; Roesel, J.; Stover, D.; et al. New aza-dipeptide analogs as potent and orally absorbed HIV-1 protease inhibitors: Candidates for clinical development. J. Med. Chem.？1998, 41, 3387–3401, doi:10.1021/jm970873c.
[54]
Robinson, B.S.; Riccardi, K.A.; Gong, Y.F.; Guo, Q.; Stock, D.A.; Blair, W.S.; Terry, B.J.; Deminie, C.A.; Djang, F.; Colonno, R.J.; et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother.？2000, 44, 2093–2099, doi:10.1128/AAC.44.8.2093-2099.2000.
Bowers, N.I.; Skonezny, P.M.; Stein, G.L.; Franceschini, T.; Chiang, S.-J.; Anderson, W.L.; You, L.; Xing, Z. Pocess for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof. WO 2006127180 A1, 30 November 2006.
[57]
Xu, Z.; Singh, J.; Schwinden, M.D.; Zheng, B.; Kissick, T.P.; Patel, B.; Humora, M.J.; Quiroz, F.; Dong, L.; Hsieh, D.-M.; et al. Process research and development for an efficient synthesis of the HIV protease inhibitor BMS-232632. Org. Process Res. Dev.？2002, 6, 323–328, doi:10.1021/op025504r.
[58]
King, A.O.; Corley, E.G.; Anderson, R.K.; Larsen, R.D.; Verhoeven, T.R.; Reider, P.J.; Xiang, Y.B.; Belley, M.; Leblanc, Y.; Labelle, M.; et al. An efficient synthesis of LTD4 antagonist L-699,392. J. Org. Chem.？1993, 58, 3731–3735, doi:10.1021/jo00066a027.
[59]
Shinkai, I.; King, A.O.; Larsen, R.D. Practical asymmetric synthesis of LTD4 antagonist. Pure Appl. Chem.？1994, 66, 1551–1556, doi:10.1351/pac199466071551.
[60]
Zhao, M.; King, A.O.; Larsen, R.D.; Verhoeven, T.R.; Reider, P.J. A convenient and economical method for the preparation of DIP-Chloride？ and its application in the asymmetric reduction of aralkyl ketones. Tetrahedron Lett.？1997, 36, 2641–2644.
[61]
Shafiee, A.; Motamedi, H.; King, A. Purification, characterization and immobilization of an NADPH-dependent enzyme involved in the chiral specific reduction of the keto ester M, an intermediate in the synthesis of an anti-asthma drug, Montelukast, from Microbacterium campoquemadoensis (MB5614). Appl. Microbiol. Biotechnol.？1998, 49, 709–717, doi:10.1007/s002530051236.
[62]
Liang, J.; Lalonde, J.; Borup, B.; Mitchell, V.; Mundorff, E.; Trinh, N.; Kochrekar, D.A.; Cherat, R.N.; Pai, G.G. Development of a biocatalytic process as an alternative to the (？)-DIP-Cl-mediated asymmetric reduction of a key intermediate of Montelukast. Org. Proc. Res. Dev.？2010, 14, 193–198, doi:10.1021/op900272d.
[63]
Holton, R.; Biediger, R.; Joatman, P. Semisynthesis of taxol and taxotere. In Taxol: Science and Application; Suffness, M., Ed.; CRC press: NewYork, NY, USA, 1995; pp. 97–123.
[64]
Kingston, D. Natural taxoids: Structure and chemistry. In Taxol: Science and Application; Suffness, M., Ed.; CRC press: NewYork, NY, USA, 1995; pp. 287–317.
[65]
Patel, R. Tour de paclitaxel: Biocatalysis for semisynthesis. Annu. Rev. Microbiol.？1995, 98, 361–395.
Junie, J.L.; Leonard, B.E. Drugs acting on sigma and phencyclidine receptors: A review of their nature, function, and possible therapeutic importance. Clin. Neuropharmacol.？1989, 12, 353–374, doi:10.1097/00002826-198910000-00001.
[68]
Ferris, C.D.; Hirsch, D.J.; Brooks, B.P.; Snyder, S.H. σ Receptors: From molecule to man. J. Neurochem.？1991, 57, 729–737, doi:10.1111/j.1471-4159.1991.tb08213.x.
[69]
Patel, R.N.; Banerjee, A.; Liu, M.; Hanson, R.; Ko, R.; Howell, J.; Szarka, L. Microbial reduction of 1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]butan-1-one. Biotechnol. Appl. Biochem.？1993, 17, 139–153.
[70]
Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K.; Himi, T. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J. Med. Chem.？1989, 32, 2583–2588.
[71]
Kagechika, H.; Shudo, K. Retinoids. Vitamin A for clinical applications. Farumashia？1990, 26, 35–40.
[72]
Moon, R.C.; Mehta, R.G. Anticarcinogenic effects of retinoids in animals. Adv. Exp. Med. Biol.？1986, 206, 399–411.
[73]
Patel, R.N.; Chu, L.; Chidambaram, R.; Zhu, J.; Kant, J. Enantioselective microbial reduction of 2-oxo-2-(1',2',3',4'-tetrahydro-1',1',4',4'-tetramethyl-6'-naphthalenyl)acetic acid and its ethyl ester. Tetrahedron Asymmetry？2002, 13, 349–355, doi:10.1016/S0957-4166(02)00109-X.
Nanduri, V.B.; Hanson, R.L.; Goswami, A.; Wasylyk, J.M.; LaPorte, T.L.; Katipally, K.; Chung, H.-J.; Patel, R.N. Biochemical approaches to the synthesis of ethyl 5-(S)-hydroxyhexanoate and 5-(S)-hydroxyhexanenitrile. Enzyme Microb. Technol.？2001, 28, 632–636, doi:10.1016/S0141-0229(01)00318-0.
[76]
Schenk, D.G.; Seubert, P. Potential treatment opportunities for Alzheimer’s disease through inhibition of secretases and Aβ immunization. J. Mol. Neurosci.？2001, 17, 259–267, doi:10.1385/JMN:17:2:259.
Wittman, M.; Carboni, J.M.; Attar, R.; Balasubramanian, B.; Balimane, P.; Brassil, P.; Beaulieu, F.; Chang, C.; Clarke, W.; Dell, J.; et al. Discovery of a 1H-Benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J. Med. Chem.？2005, 48, 5639–5643, doi:10.1021/jm050392q.
[79]
Carboni, J.M.; Hurlburt, W.W.; Gottardis, M.M. Synergistic methods and compositions for treating cancer. WO 2004030625 A2, 15 April 2004.
[80]
Beaulieu, F.; Ouellet, C.; Zimmermann, K.; Velaparthi, U.; Wittman, M.D. Novel tyrosine kinase inhibitors. WO 2004063151 A3, 9 December 2004.
[81]
Hanson, R.L.; Goldberg, S.; Goswami, A.; Tully, T.P.; Patel, R.N. Purification and cloning of a ketoreductase used for the preparation of chiral alcohols. Adv. Synth. Catal.？2005, 347, 1073–1080, doi:10.1002/adsc.200505045.
[82]
Vacca, J.P. New advances in the discovery of thrombin and factor Xa inhibitors. Curr. Opin. Chem. Biol.？2000, 4, 394–400, doi:10.1016/S1367-5931(00)00112-5.
[83]
Gladwell, T.D. Bivalirudin: A direct thrombin inhibitor. Clin. Ther.？2002, 24, 38–58, doi:10.1016/S0149-2918(02)85004-4.
[84]
Fevig, J.M.; Wexler, R.R. Anticoagulants: Thrombin and factor Xa inhibitors. Annu. Rep. Med. Chem.？1999, 34, 81–100, doi:10.1016/S0065-7743(08)60571-0.
[85]
Williams, P.D.; Coburn, C.; Burgey, C.; Morrissette, M.M. Preparation of Triazolopyrimidines as Thrombin Inhibitors. WO 2002064211 A1, 22 August 2002.
[86]
Nelson, T.D.; LeBlond, C.R.; Frantz, D.E.; Matty, L.; Mitten, J.V.; Weaver, D.G.; Moore, J.C; Kim, J.M.; Boyd, R.; Kim, P.-Y.; et al. Stereoselective synthesis of a potent thrombin inhibitor by a novel P2-P3 lactone ring opening. J. Org. Chem.？2004, 69, 3620–3627, doi:10.1021/jo035794p.
[87]
Fukuroda, T.; Nishikibe, M. Enhancement of pulmonary artery contraction induced by endothelin-β receptor antagonism. J. Cardiovasc. Pharmacol.？1998, 31, S169–S171, doi:10.1097/00005344-199800001-00048.
[88]
Sumner, M.J.; Cannon, T.R.; Mundin, J.W.; White, D.G.; Watts, I.S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br. J. Pharmacol.？1992, 107, 858–860, doi:10.1111/j.1476-5381.1992.tb14537.x.
[89]
Krulewicz, B.; Tschaen, D.; Devine, P.; Lee, S.S.; Roberge, C.; Greasham, R.; Chartrain, M. Asymmetric biosynthesis of key aromatic intermediates in the synthesis of an endothelin receptor antagonist. Biocatal. Biotransformation？2001, 19, 267–279, doi:10.3109/10242420109003644.
[90]
Chaffman, M.; Brogden, R.N. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs？1985, 29, 387–390, doi:10.2165/00003495-198529050-00001.
[91]
Kawai, C.; Konishi, T.; Matsuyama, E.; Okazaki, H. Comparative effects of three calcium antagonists, diatiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies. Circulation？1981, 63, 1035–1038, doi:10.1161/01.CIR.63.5.1035.
[92]
Isshiki, T.; Pegram, B.; Frohlich, E. Immediate and prolonged hemodynamic effects of TA-3090 on spontaneously hypertensive (SHR) and normal Wistar-Kyoto (WKY) rats. Cardiovasc. Drug Ther.？1988, 2, 539–544, doi:10.1007/BF00051194.
Patel, R.N.; Banerjee, A.; Chu, L.; Brzozowski, D.; Nanduri, V.; Szarka, L.J. Microbial synthesis of chiral intermediates for β-3-receptor agonists. J. Am. Oil Chem. Soc.？1998, 75, 1473–1482, doi:10.1007/s11746-998-0081-0.
[99]
Iwata, H.; Tanaka, R.; Ishiguro, M. Structures of the alkaline hydrolysis products of penem antibiotic, SUN5555. J. Antibiot.？1990, 43, 901–903, doi:10.7164/antibiotics.43.901.
[100]
Jean-Paul Vandecasteele, J.-P. Enzymatic synthesis of l-carnitine by reduction of an achiral precursor: The problem of reduced nicotinamide adenine dinucleotide recycling. Appl. Environ. Microbiol.？1980, 39, 327–334.
[101]
Yamamoto, H; Matsuyama, A.; Kobayashi, Y. Synthesis of (R)-1,3-butanediol by enantioselective oxidation using whole recombinant Escherichia coli cells expressing (S)-specific secondary alcohol dehydrogenase. Biosci Biotechnol Biochem.？2002, 66, 925–927, doi:10.1271/bbb.66.925.
[102]
Coleman, P.J.; Brashear, K.M.; Askew, B.C. Nonpeptide α vβ 3 antagonists. Part 11: Discovery and preclinical evaluation of potent α vβ3 antagonists for the prevention and treatment of osteoporosis. J. Med. Chem.？2004, 47, 4829–4837, doi:10.1021/jm049874c.
[103]
Pollard, D.J.; Telari, K.; Lane, J.; Humphrey, G.; McWilliams, C.; Nidositko, S.; Salmon, P.; Moore, J. Asymmetric reduction of alpha, beta-unsaturated ketone to (R) allylic alcohol by Candida chilensis. Biotechnol. Bioeng.？2006, 93, 674–684, doi:10.1002/bit.20751.
[104]
Brands, K.M.J.; Payack, J.F.; Rosen, J.D.; Nelson, T.D.; Candelario, A.; Huffman, M.A.; Zhao, M.M.; Bridgette, J.L.; Zhiguo, C.J.; Song, D.M.; et al. Efficient synthesis of NK1 receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation. J. Am. Chem. Soc.？2003, 125, 2129–2135, doi:10.1021/ja027458g.
[105]
Pollard, D.; Truppo, M.; Pollard, J.; Chen, C.-Y.; Moore, J. Effective synthesis of (S)-3,5-bistrifluoro methylphenyl ethanol by asymmetric enzymatic reduction. Tetrahedron Asymmetry？2006, 17, 554–559, doi:10.1016/j.tetasy.2006.01.039.
[106]
Patel, R.N. Chemo-enzymatic synthesis of pharmaceutical intermediates. Expert Opin. Drug Dis. Dev.？2008, 3, 187–245, doi:10.1517/17460441.3.2.187.
[107]
Ohshima, T.; Soda, K. Stereoselective Biocatalysis: Amino Acid Dehydrogenases and Their Applications in Stereoselective Biocatalysis; Patel, R.N., Ed.; Marcel and Dekker Pub: New York, New York, USA, 2000; pp. 877–903.
[108]
Wandrey, C.; Wichman, R.; Leuchtenberger, W. Continuous Enzymic Transformation of Water-Soluble α-Keto Carboxylic Acids into the Corresponding Amino Acids. EP 0023346 B1, 13 July 1983.
[109]
Brunhuber, N.M.; Blanchard, J.S. The biochemistry and enzymology of amino acid dehydrogenases. Crit. Rev. Biochem. Mol. Biol.？1994, 29, 415–467, doi:10.3109/10409239409083486.
Godfrey, J.D.; Mueller, R.H.; van Langen, D.J. β-Lactam synthesis: Cyclization versus 1,2-acyl migration-cyclization. The mechanism of the 1,2-acyl migration-cyclization. Tetrahedron Lett.？1986, 27, 2793–2796, doi:10.1016/S0040-4039(00)84644-4.
[112]
Hanson, R.L.; Singh, J.; Kissick, T.P.; Patel, R.N.; Szarka, L.; Mueller, R. Synthesis of L-β-hydroxyvaline from α-keto-β-hydroxyisovalerate using leucine dehydrogenase from Bacillus species. Bioorg. Chem.？1990, 18, 116–130, doi:10.1016/0045-2068(90)90033-2.
Stoyan, T.; Recktenwald, A.; Kula, M.R. Cloning, sequencing and overexpression of the leucine dehydrogenase gene from Bacillus cereus. J. Biotechnol.？1997, 54, 77–80, doi:10.1016/S0168-1656(97)01670-2.
[115]
Menzel, A.; Werner, H.; Altenbuchner, J.; Groger, H. From enzymes to “designer bugs” in reductive amination: A new process for the synthesis of L-tert-leucine using a whole cell. Eng. Life Sci.？2004, 4, 573–576, doi:10.1002/elsc.200402162.
[116]
Robl, J.; Sun, C.; Stevenson, J.; Ryono, D.; Simpkins, L.; Cimarusti, M.; Dejneka, T.; Slusarchyk, W.; Chao, S.; Stratton, L.; et al. Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem.？1997, 40, 1570–1577, doi:10.1021/jm970041e.
Patel, R. Enzymatic synthesis of chiral intermediates for Omapatrilat, an antihypertensive drug. Biomol. Eng.？2001, 17, 167–182, doi:10.1016/S1389-0344(01)00068-5.
[119]
Hanson, R.L.; Howell, J.; LaPorte, T.; Donovan, M.; Cazzulino, D.; Zannella, V.; Montana, M.; Nanduri, V.; Schwarz, S.; Eiring, R.; et al. Synthesis of allylsine ethylene acetal using phenylalanine dehydrogenase from Thermoactinomyces intermedius. Enzyme Microb. Technol.？2000, 26, 348–358, doi:10.1016/S0141-0229(99)00175-1.
[120]
Gallwitz, B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat. Endocrinol.？2005, 4, 361–370, doi:10.2165/00024677-200504060-00005.
[121]
Sinclair, E.M.; Drucker, D.J. Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: New therapeutic agents for the treatment of type 2 diabetes. Curr. Opin. Endocrinol. Diabet.？2005, 12, 146–151, doi:10.1097/01.med.0000155379.11926.e2.
[122]
Augeri, D.J.; Robl, J.A.; Betebenner, D.A.; Magnin, D.R.; Khanna, A.; Robertson, J.G.; Wang, A.; Simpkins, L.M.; Taunk, P.; Huang, Q.; et al. A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem.？2005, 48, 5025–5037, doi:10.1021/jm050261p.
[123]
Augeri, D.J.; Betebenner, D.A.; Hamann, L.G.; Magnin, D. R.; Robl, J.A.; Sulsky, R.B. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation and their use. WO 2001068603 A2, 20 September 2001.
[124]
Hanson, R.L.; Goldberg, S.L.; Brzozowski, D.B.; Tully, T.P.; Cazzulino, D.; Parker, W.L.; Lyngberg, O.K.; Vu, T.C.; Wong, M.K.; Patel, R.N. Preparation of an amino acid intermediate for the dipeptidyl peptidase IV inhibitor, saxagliptin, using a modified phenylalanine dehydro genase. Adv. Synth. Catal.？2007, 349, 1369–1378, doi:10.1002/adsc.200700013.
[125]
Groeger, H.; May, O.; Werner, H.; Menzel, A.; Altenbuchner, J. A “second-generation process” for the synthesis of L-neopentylglycine: Asymmetric reductive amination using a recombinant whole cell catalyst. Org. Process Res. Dev.？2006, 10, 666–669, doi:10.1021/op0501702.
[126]
Emmanuel, M.J.; Frye, L.L.; Hickey, E.R.; Liu, W.; Morwick, T.M.; Spero, D.M.; Sun, S.; Thomson, D.S.; Ward, Y.D.; Young, E.R.R. Novel Spiroheterocyclic Compounds [Morpholine-4-Carboxylic Acid Amides of Heterocyclic Cyclohexylalanine and Neopentylglycine Derivatives and Their Analogs], Useful as Reversible Inhibitors of Cysteine Proteases such as Cathepsin S. WO 2001019816 A1 22 May 2001.
[127]
Haque, T.S.; Ewing, W.R.; Mapelli, C.; Lee, V.G.; Sulsky, R.B.; Riexinger, D.J.; Martinez, R.L.; Zhu, Y.Z. Human Glucagon-like-Peptide-1 Modulators and Their Use in the Treatment of Diabetes and Related Conditions. WO2007082264, A2, 11 January 2007.
Chen, Y.; Goldberg, S.L.; Hanson, R.L.; Parker, W.L.; Gill, I.; Tully, T.P.; Montana, M.; Goswami, A.; Patel, R.N. Enzymatic preparation of an (S)-amino acid from a racemic amino acid. Org. Process Res. Dev.？2011, 15, 241–248, doi:10.1021/op1001534.
[130]
Straathof, A.J.J.; Panke, S.A. The production of fine chemicals by biotransformations. Curr. Opin. Biotechnol.？2002, 13, 548–556, doi:10.1016/S0958-1669(02)00360-9.
[131]
Bommarius, A.S.; Schwarm, M.; Drauz, K. Biocatalysis to amino acid-based chiral pharmaceuticals-examples and perspectives. J. Mol. Catal. B Enzym.？1998, 5, 1–11, doi:10.1016/S1381-1177(98)00009-5.
[132]
Vedha-Peters, K.; Gunawardana, M.; Rozzell, J.D.; Novick, S.J. Creation of a broad-range and highly stereoselective D-amino acid dehydrogenase for the one-step synthesis of D-amino acids. J. Am. Chem. Soc.？2006, 128, 10923–10929.
[133]
Gustafsson, D.; Elg, M.; Lenfors, S.; Boerjesson, I.; Teger-Nilsso, A.-C. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul. Fibrinolysis？1996, 7, 69–79, doi:10.1097/00001721-199601000-00009.
[134]
Alexandre, F.-R.; Pantaleone, D.P.; Taylor, P.P.; Fotheringham, I.G.; Ager, D.J.; Turner, N.J. Amine-boranes: Effective reducing agents for the deracemisation of DL-amino acids using L-amino acid oxidase from Proteus myxofaciens. Tetrahedron Lett.？2002, 43, 707–710.
[135]
Chaturvedula, P.V.; Chen, L.; Civiello, R.; Degnan, A.P.; Dubowchik, G.M.; Han, X.; Jiang, J.J.; Macor, J.E.; Poindexter, G.S.; Tora, G.O.; et al. Anti-Migraine Spirocycles. US 7842808 B2, 5 January 2007.
[136]
Han, X.; Civiello, R.L.; Conway, C.M.; Cook, D.A.; Davis, C.D.; Macci, R.; Pin, S.S.; Ren, S.X.; Schartman, R.; Signor, L.J.; Thalody, G.; Widmann, K.A.; Xu, C.; Chaturvedula, P.V.; Macor, J.E.; Dubowchik, G.M. The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1. Bioorg Med Chem Lett.？2012, 22, 4723–4727, doi:10.1016/j.bmcl.2012.05.074.
[137]
Hanson, R.L.; Davis, B.L.; Goldberg, S.L.; Johnston, R.M.; Parker, W.L.; Tully, T.P.; Montana, M.A.; Patel, R.N. Enzymatic preparation of a D-amino acid from a racemic amino acid or keto acid. Org. Process Res. Dev.？2008, 12, 1119–1129, doi:10.1021/op800149q.
[138]
Ising, M.; Zimmermann, U.S.; Künzel, H.E.; Uhr, M.; Foster, A.C.; Learned-Coughlin, S.M.; Holsboer, F.; Grigoriadis, D.E. High-affinity CRF1 receptor antagonist NBI-34041: Preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology？2007, 32, 1941–1949, doi:10.1038/sj.npp.1301328.
[139]
Overstreet, D.H.; Griebel, G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur. J. Pharmacol.？2004, 497, 49–53, doi:10.1016/j.ejphar.2004.06.035.
[140]
Tache, Y.; Martinez, V.; Wang, L.; Million, M. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: Implications for irritable bowel syndrome. Br. J. Phamacol.？2004, 141, 1321–1330, doi:10.1038/sj.bjp.0705760.
[141]
Yu, W.-L.; Lawrence, F.; Wong, H.; Lelas, S.; Zhang, G.; Lindner, M.D.; Wallace, T.; McElroy, J.; Lodge, N.J.; Gilligan, P.; et al. The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists. CNS Drug Rev.？2006, 11, 21–52, doi:10.1111/j.1527-3458.2005.tb00034.x.
[142]
Gilligan, P.J.; Clarke, T.; He, L.; Lelas, S.; Li, Y.-W.; Heman, K.; Fitzgerald, L.; Miller, K.; Zhang, G.; Marshall, A.; et al. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: Selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. J. Med. Chem.？2009, 52, 3084–3092, doi:10.1021/jm900025h.
[143]
Hanson, R.L.; Davis, B.L.; Chen, Y.; Goldberg, S.L.; Parker, W.L.; Tully, T.P.; Montana, M.A.; Patel, R.N. Preparation of (R)-amines from racemic amines with an (S)-amine transaminase from Bacillus megaterium. Adv. Synth. Catal.？2008, 350, 1367–1375, doi:10.1002/adsc.200800084.
